There is a reporting error in the figure legend of [Fig 1](#pone.0237035.g001){ref-type="fig"}. The number of animals included in each group should read n = 8--11, as opposed to the originally reported n = 9--12. Please see the complete, correct figure caption here.

![SS treatment ameliorates learning and memory impairment in Morris Water Maze and Object recognition test.\
**(A)** MWM test for SS and vehicle-treated APP/PS1 and WT mice. The mean escape latency was given for different test days. **(B)** The mean percent time in probe trial of MWM on day 7. TQ: Target quadrant; AL: Adjacent left; AR: Adjacent right; OP: Opposite. **(C)** Representative mice search paths from different groups. **(D and E)** The latency to target quadrant **(D)** and the frequency to pass the target position **(E)** in probe trial are shown. **(F and G)** The swimming velocity **(F)** and distance **(G)** in probe trial are shown. **(H and I)** Novel object recognition analysis. Preference scores of training phase **(H)** and Recognition Index of testing phase **(I)** during a 10-min testing phase are shown, respectively. n  =  8--11 for each group. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001, \#*P*\<0.05, \#\#*P*\<0.01, \#\#\#*P*\<0.001.](pone.0237035.g001){#pone.0237035.g001}

The Cortex panels for CD11b WT Veh and APP/PS1 SS in [Fig 2I](#pone.0237035.g002){ref-type="fig"} appear similar. The authors have indicated that wrong cortex panel for CD11b APP/PS1 SS has been used inadvertently during the preparation of the figure. The authors have provided an updated version of [Fig 2](#pone.0237035.g002){ref-type="fig"} showing the correct panel. The original images underlying the panels presented in [Fig 2](#pone.0237035.g002){ref-type="fig"} have been uploaded as a supplementary file.

![SS treatment alleviates Aβ levels and amyloid plaque burden, reduces gliosis and neuron loss in APP/PS1 mice.\
**(A--C)** Representative half brain sections of WT mice, vehicle or SS-treated APP/PS1 mice stained with antibody against Aβ (6E10) and double staining of GFAP and 6E10 are shown. Scale bar, 1 mm. (**B** and **C**) Quantitative analysis of the number of 6E10-positive amyloid plaques (**B**) and Aβ covered area (**C**). n  =  5 animals per group. (**D** and **E**) ELISA of soluble and insoluble Aβ~**40**~ and Aβ~**42**~ levels in cortical and hippocampal tissues of APP/PS1 mice. n  =  6 for each group. (**F**, **I** and **J**) Representative images of WT mice, vehicle- and SS- treated APP/PS1 mice hippocampus and cortex double immunostaining of GFAP and 6E10 (**F**), CD11b (**I**) and NeuN (**J**). Arrows indicate astrocytes surrounding the amyloid plaques. Scale bar, 200 µm. (**H**) Coincidence of GFAP and Aβ burden in the brains of SS-treated APP/PS1 mice (red; n  =  17) and vehicle-treated APP/PS1 mice (black; n  =  17; *P*\<0.0001). (**G**, **K** and **L**) The histograms depict the mean GFAP (**G**), CD11b (**K**), and NeuN (**L**) positive area ± S.E.M. in three groups. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001.](pone.0237035.g002){#pone.0237035.g002}

To improve the reproducibility of this study, the authors have provided additional details regarding the ingredients used to prepare the Smart Soup:

"The CFDA-approved single-herb granules of Rhizoma Acori Tatarinowii (AT), Poria cum Radix Pini (PRP) and Radix Polygalae (RP) were obtained from Tianjiang Pharmaceutical, Jiangyin, China:

AT product name: Shi Chang Pu, lot number: 1112134;

PRP product name: Fu Shen, lot number: 1103019;

RP product name: Zhi Yuan Zhi, lot number: 1102028."

The authors have provided the underlying individual level data for their manuscript, which have been uploaded as Supporting Information Files. The original images underlying [Fig 1C](#pone.0237035.g001){ref-type="fig"} and Fig 7E are available from the authors upon request.
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###### Uncropped images underlying [Fig 2A](#pone.0237035.g002){ref-type="fig"}.
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Click here for additional data file.

###### Uncropped images underlying [Fig 2F](#pone.0237035.g002){ref-type="fig"}.
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Click here for additional data file.

###### Uncropped images underlying [Fig 2I](#pone.0237035.g002){ref-type="fig"}.
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Click here for additional data file.

###### Uncropped images underlying [Fig 2J](#pone.0237035.g002){ref-type="fig"}.
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Click here for additional data file.

###### Individual level data underlying [Fig 1A, 1B and 1D--1I](#pone.0237035.g001){ref-type="fig"}.
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Click here for additional data file.

###### Individual level data underlying [Fig 2B--2E, 2G, 2H, 2K and 2L](#pone.0237035.g002){ref-type="fig"}.
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Click here for additional data file.

###### Individual level data underlying Fig 3A--3F.
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Click here for additional data file.

###### Individual level data underlying Fig 4A--4C.
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###### Individual level data underlying Fig 5A--5D.
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Click here for additional data file.

###### Individual level data underlying Fig 6A--6D.
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Click here for additional data file.

###### Individual level data underlying Fig 7A--7D and 7F.
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Click here for additional data file.
